MicroWash
Private Company
Funding information not available
Overview
MicroWash, developed by University Medical Devices, is commercializing a patented nasal lavage device that represents a potential paradigm shift in respiratory specimen collection. The device claims significant advantages over nasal swabs, including up to 49% greater PCR sensitivity, a three-year shelf life, a defined reimbursement pathway, and a vastly improved patient comfort rating (0.3/10 vs. 8/10 for swabs). Targeting the diagnostics and digital health sectors, the company is leveraging its leadership's clinical and biocontainment expertise to establish MicroWash as the new gold standard for nasal sampling in a post-pandemic world.
Technology Platform
Patented single-use nasal lavage device that uses sterile saline to collect upper respiratory infection (URI) samples for PCR testing, claiming greater sensitivity, patient comfort, and shelf-life than traditional swabs.
Opportunities
Risk Factors
Competitive Landscape
MicroWash's direct competitors are manufacturers of traditional nasal and nasopharyngeal swabs, which are commodity products with vast scale and low cost. Indirect competitors include other novel specimen collection methods (e.g., saliva collection kits, less invasive swabs). Its competitive edge lies in its combined claims of superior sensitivity, patient comfort, and a unique reimbursement pathway, but it must overcome the immense inertia of the existing swab-based ecosystem.